Equities
Health CareMedical Equipment and Services
  • Price (USD)325.58
  • Today's Change1.89 / 0.58%
  • Shares traded159.59k
  • 1 Year change+6.34%
  • Beta0.9038
Data delayed at least 15 minutes, as of Nov 21 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Its Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes and food testing regimes. The Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are primarily sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

  • Revenue in USD (TTM)2.58bn
  • Net income in USD-778.69m
  • Incorporated1975
  • Employees8.03k
  • Location
    Bio Rad Laboratories Inc1000 ALFRED NOBEL DRHERCULES 94547-1811United StatesUSA
  • Phone+1 (510) 724-7000
  • Fax+1 (510) 741-5817
  • Websitehttps://www.bio-rad.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Procept Biorobotics Corp199.84m-100.06m5.01bn626.00--20.04--25.08-1.95-1.953.894.630.50261.833.86319,238.00-25.16---28.58--57.39---50.07--5.07--0.1758--81.55---21.51------
Stevanato Group SpA1.15bn120.92m5.53bn5.64k40.573.5827.174.800.45030.45034.285.110.52842.752.66204,699.805.54--7.39--29.20--10.48--1.2148.530.2148--10.34--1.95------
Inspire Medical Systems Inc755.59m33.05m5.54bn1.01k169.807.95145.697.331.091.0925.1523.251.052.469.37747,372.904.60-11.275.12-12.6084.7784.474.37-13.576.94--0.00--53.1965.3252.87--148.37--
Lantheus Holdings Inc1.50bn427.61m6.01bn834.0014.375.0912.274.026.026.0221.0916.970.83838.285.091,794,723.0023.956.6932.767.7364.7857.5628.579.021.56--0.3240.0038.6530.441,063.8651.8135.48--
Merit Medical Systems Inc1.33bn120.04m6.07bn6.95k50.994.5827.864.572.042.0422.5522.710.63342.297.41190,772.805.732.456.322.7746.8344.509.053.913.8231.880.36190.009.247.3326.7015.86-11.16--
Repligen Corp622.64m-17.13m7.78bn1.78k--3.86151.6012.49-0.3079-0.307911.0936.000.2331.575.29349,206.40-0.64114.38-0.70325.0350.3755.43-2.7515.918.76--0.20550.00-20.3126.91-77.6420.1324.99--
Glaukos Corp360.35m-149.57m7.80bn907.00--11.66--21.64-2.96-2.967.0612.130.38431.697.53397,295.50-15.95-8.73-17.23-9.3576.6174.77-41.51-28.694.71-311.240.1591--11.2611.66-35.75--14.44--
Bruker Corp3.24bn304.90m8.09bn9.71k25.734.4817.142.502.072.0721.8911.920.65271.515.73333,913.706.128.388.1411.4049.3149.859.3811.390.708526.830.55499.8117.149.3644.0318.9116.794.56
Teleflex Inc3.03bn238.01m8.70bn14.50k37.161.9417.242.885.045.0364.0196.500.4042.116.76208,677.503.185.863.466.4255.9954.437.8714.621.396.610.281815.846.573.97-1.4712.732.510.00
Masimo Corp2.04bn78.60m8.83bn3.80k113.456.0350.964.321.451.4537.7227.350.67151.775.52537,526.302.588.653.2310.3150.0557.303.8512.031.112.840.34560.000.604219.00-43.21-15.9631.06--
Bio Rad Laboratories Inc2.58bn-778.69m9.12bn8.03k--1.21--3.53-27.32-27.3290.77267.460.22941.495.61321,321.20-6.929.08-7.269.6054.4355.55-30.1841.974.520.26120.13830.00-4.673.1382.43--3.83--
Penumbra Inc1.16bn34.55m9.18bn4.20k278.078.31150.747.890.86020.860229.7128.780.78971.046.08277,089.502.342.322.612.6165.7063.902.973.173.25--0.02180.0024.9518.934,643.1668.609.64--
Henry Schein, Inc.12.50bn314.00m9.19bn25.00k30.192.6315.530.73552.442.4496.8927.991.224.777.73499,960.002.976.094.8610.4431.5930.042.424.400.8176.230.3480.00-2.445.55-22.68-0.145621.27--
Solventum Corp8.22bn720.00m11.81bn22.01k16.423.709.341.444.164.1647.4518.480.58313.937.19373,290.305.11--6.03--56.38--8.76--0.82685.020.7176--0.8241--0.2234------
Data as of Nov 21 2024. Currency figures normalised to Bio Rad Laboratories Inc's reporting currency: US Dollar USD

Institutional shareholders

42.41%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 20241.88m8.25%
BlackRock Fund Advisorsas of 30 Sep 20241.54m6.77%
Van Eck Associates Corp.as of 30 Sep 20241.30m5.72%
Veritas Asset Management LLPas of 30 Sep 20241.09m4.77%
First Eagle Investment Management LLCas of 30 Sep 2024713.00k3.13%
Select Equity Group LPas of 30 Sep 2024708.45k3.11%
SSgA Funds Management, Inc.as of 30 Sep 2024635.92k2.79%
Dimensional Fund Advisors LPas of 30 Sep 2024608.05k2.67%
EARNEST Partners LLCas of 30 Sep 2024605.55k2.66%
Millennium Management LLCas of 30 Sep 2024583.80k2.56%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.